Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) can be technically complex. Coronary computed tomography angiography (CTA) is increasingly being used for planning CTO PCI. Coronary CTA can help evaluate cap morphology, lesion length, calcification, and distal vessel quality. The use of coronary CTA for CTO PCI may be enhanced by integration with artificial intelligence and real-time imaging. In a randomized controlled trial, preprocedural coronary CTA increased the success of CTO PCI. In this review, the authors describe how coronary CTA can help diagnose and characterize CTO lesions, estimate the time needed for guidewire crossing time, predict and facilitate CTO PCI technical success, and provide real-time procedural guidance.
Hypoxia is involved in severe cardiac conditions such as heart failure and myocardial infarction. Therefore, understanding the molecular mechanisms underlying hypoxia is crucial for developing effective therapeutic strategies. Specifically, one in vitro hypoxia model involves reducing oxygen concentration, thereby emulating many features observed in cardiac ischemia in rodents and patients. One way to overcome the infrastructure challenges in basic research laboratories (e.g., anaerobic chamber) is to use chemically-induced hypoxia models. Cobalt chloride (CoCl2) treatment provides an inexpensive, accessible, and highly reproducible model in diverse cell types, as it mimics many of the cellular processes activated during hypoxia/ischemia. Paradoxically, no compendium addresses these processes beyond oxidative stress, let alone focusing on cardiac tissue. Hence, our objective was to describe how other processes, such as mitochondrial dysfunction, calcium handling, apoptosis, autophagy, inflammation, and endoplasmic reticulum stress, interact negatively in cardiac cells exposed to CoCl2 and to examine their cardiomyocyte-level toxicological effects.
The prognostic role of high-risk plaque (HRP) features, including high coronary calcium scores detected by CT, beyond traditional cardiovascular risk factors and obstructive coronary artery disease (CAD), remains uncertain. This study evaluated the prognostic value of a combined HRP definition in stable chest pain patients with low-to-intermediate pretest probability of CAD. This prespecified analysis included participants randomized to the CT arm of the pragmatic, prospective 26-center European DISCHARGE trial (NCT02400229). The primary endpoint was major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, or stroke); the secondary endpoint was expanded MACE (transient ischemic attack and major procedure-related complications). Our combined HRP definition was any coronary plaque with positive remodeling, napkin-ring sign, low attenuation, or total calcium score ≥ 400 Agatston units. Among 1745 participants (age: 60 ± 10 years, 990 female), 35 MACE and 47 expanded MACE occurred at a median follow-up of 3.5 years (IQR: 2.9–4.2). After risk factor adjustment, the combined HRP definition was associated with a higher risk of MACE (HR: 3.81; 95
INTRODUCTION:Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently recommended as one of the four pillars of treatment in heart failure (HF) with reduced ejection fraction (HFrEF). Following the approval of dapagliflozin in 2020, real-world data are relevant for the medical community and payers. This study aimed to characterize the patient population with dapagliflozin initiated for HFrEF in clinical practice in 9 countries from Central Eastern Europe and the Baltic Area (CEE-BA). METHODS:EVOLUTION-HF CEE-BA is a multicentre, multi-country, observational, longitudinal study conducted in 102 centres in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, and Slovenia. All treatment decisions were at the discretion of the patient's healthcare providers, based on the locally approved product information and routine clinical practice. Patients with type 1 diabetes, prior treatment with dapagliflozin or other SGLT2i, and initiation of dapagliflozin outside the approved HFrEF indication were excluded. The baseline period covered 12 months prior to dapagliflozin initiation, with prospective follow-up continuing up to 12 months or until loss to follow-up, death, or study discontinuation, whichever occurred first. Descriptive statistics and Kaplan-Meier methods were used. RESULTS:A total of 1131 patients with HFrEF were included in the full analysis set. Ischaemic aetiology was present in 52% of patients. The mean left ventricular ejection fraction was 32%. The most frequent comorbidities were atrial fibrillation (46%), type 2 diabetes (37%), and chronic kidney disease (29%). At the time of dapagliflozin initiation, 93% of patients received any combination of a renin-angiotensin-aldosterone system inhibitor (RAASi), beta-blocker (BB), or mineralocorticoid receptor antagonists (MRA). Of all patients, 60% received concomitantly all three classes plus dapagliflozin for their HFrEF. Except for dapagliflozin, which was administered as 10 mg/day, optimal doses were recorded for 14% for any RAASi, 17% for BB, and 25% for MRA. At 6- and 12-month follow-up, maintenance of dapagliflozin treatment was recorded in 95% and 96% of patients, respectively. The real-world median time to discontinuation of dapagliflozin has not been reached. The percentage of patients receiving all four classes recommended in HFrEF remained stable over the study period. Adverse events were reported spontaneously, as in routine clinical practice in each centre. CONCLUSION:This large non-interventional study provides a contemporary perspective of the treatments used in HFrEF over 1-year follow-up. Despite high dapagliflozin persistence rates, a low proportion of patients received complete guideline-directed medical therapy in optimal doses. Improvement of HF management decisions across the CEE-BA region is warranted.
Previous studies suggest that HDLs may protect against the effects of acute injury. Given their multiple beneficial properties, this study aimed to investigate whether exogenous HDLs administration reduces acute tissue damage in a HgCl2-induced renal injury model, potentially contributing to health improvement and disease prevention. Acute tubular injury was induced in male Wistar rats with a single intraperitoneal dose of 3.5 mg/kg HgCl2 (ATI group). Two additional groups received either HDLs (ATI + HDL group) or apolipoprotein B-containing lipoproteins (ATI + Lp-B) isolated from human plasma, at a dose equivalent to 0.9 mg of cholesterol per 100 g of body weight, administered twice on consecutive days. The study follow-up lasted four days. Urine and blood samples were collected to evaluate renal function markers. Histological analysis was also performed. In vitro, the ability of these lipoproteins to maintain cell viability under mercury exposure was assessed using the HEK-293 cell line. During the follow-up, plasma creatinine decreased, creatinine clearance improved, and proteinuria levels recovered more rapidly in the ATI + HDL group than in the ATI group. Glucosuria remained similar across both groups throughout the study. Histological analysis revealed increased cellularity and reduced necrosis in the kidneys of the ATI + HDL group compared to ATI rats. Rats in the ATI + Lp-B group died 48 h after HgCl2 administration and tubular lesions were more severe. In vitro, HDLs effectively preserved cell viability under mercury exposure, while Lp-B did not provide similar protection. Exogenous HDLs supplementation improves biochemical markers of renal function in vivo and promotes cell survival in vitro in a HgCl2 toxicity model. These findings reveal a new beneficial property of HDLs, unlike apo B-containing lipoproteins, and underline the importance of such interventions for health support and disease management.